269 related articles for article (PubMed ID: 35525905)
1. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract][Full Text] [Related]
2. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.
Yu X; Li D; Kottur J; Kim HS; Herring LE; Yu Y; Xie L; Hu X; Chen X; Cai L; Liu J; Aggarwal AK; Wang GG; Jin J
J Med Chem; 2023 Dec; 66(23):16168-16186. PubMed ID: 38019706
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
6. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
Yu X; Li D; Kottur J; Shen Y; Kim HS; Park KS; Tsai YH; Gong W; Wang J; Suzuki K; Parker J; Herring L; Kaniskan HÜ; Cai L; Jain R; Liu J; Aggarwal AK; Wang GG; Jin J
Sci Transl Med; 2021 Sep; 13(613):eabj1578. PubMed ID: 34586829
[TBL] [Abstract][Full Text] [Related]
7. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
9. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
10. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
11. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
12. UBE2G1 governs the destruction of cereblon neomorphic substrates.
Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
Elife; 2018 Sep; 7():. PubMed ID: 30234487
[TBL] [Abstract][Full Text] [Related]
13. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
[TBL] [Abstract][Full Text] [Related]
14. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.
Kabir M; Qin L; Luo K; Xiong Y; Sidi RA; Park KS; Jin J
J Med Chem; 2024 Apr; 67(8):6880-6892. PubMed ID: 38607318
[TBL] [Abstract][Full Text] [Related]
16. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
17. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
18. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
19. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
[TBL] [Abstract][Full Text] [Related]
20. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]